pHIV-NAT-T2A-hCD52-eGFP-NFATC2IP-SPR
(Plasmid
#221447)
-
PurposeLentiviral mammalian expression vector of eGFP-tagged NFATC2IP ORF that is fused with S-phase restricted (SPR) degron at its C-terminus
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 221447 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 * |
* Log in to view industry pricing.
Backbone
-
Vector backbonepHIV-NAT-T2A-hCD52
-
Backbone manufacturerRalph Scully
- Backbone size w/o insert (bp) 9173
- Total vector size (bp) 10427
-
Vector typeMammalian Expression, Lentiviral
-
Selectable markersNourseothricin (clonNAT)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameNFATC2IP
-
SpeciesH. sapiens (human)
-
Insert Size (bp)1254
-
MutationSPR degron: hGEM (1-110) fragment that is fused to hSLBP (18-108), with GGGS linker in between. 1st Methionine of NFATC2IP deleted
-
Entrez GeneNFATC2IP (a.k.a. ESC2, NIP45, RAD60)
- Promoter CMV
-
Tag
/ Fusion Protein
- eGFP (N terminal on insert)
Cloning Information
- Cloning method Other
- 5′ sequencing primer cgcaaatgggcggtaggcgtg (Common Sequencing Primers)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pHIV-NAT-T2A-hCD52-eGFP-NFATC2IP-SPR was a gift from Daniel Durocher (Addgene plasmid # 221447 ; http://n2t.net/addgene:221447 ; RRID:Addgene_221447) -
For your References section:
NFATC2IP is a mediator of SUMO-dependent genome integrity. Cho T, Hoeg L, Setiaputra D, Durocher D. Genes Dev. 2024 Apr 17;38(5-6):233-252. doi: 10.1101/gad.350914.123. 10.1101/gad.350914.123 PubMed 38503515